Item Type | Name |
Concept
|
Psoriasis
|
Academic Article
|
Comparative tolerability of systemic treatments for plaque-type psoriasis.
|
Academic Article
|
Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial.
|
Academic Article
|
Adalimumab: efficacy and safety in psoriasis and rheumatoid arthritis.
|
Academic Article
|
A randomized trial of etanercept as monotherapy for psoriasis.
|
Academic Article
|
Biologic therapy for psoriasis: the new therapeutic frontier.
|
Academic Article
|
Extended efalizumab therapy sustains efficacy without increasing toxicity in patients with moderate to severe chronic plaque psoriasis.
|
Academic Article
|
The immunology of psoriasis and biologic immunotherapy.
|
Academic Article
|
Patient education and advocacy groups: a means to better outcomes?
|
Academic Article
|
Definitions of measures of effect duration for psoriasis treatments.
|
Academic Article
|
Efalizumab retreatment in patients with moderate to severe chronic plaque psoriasis.
|
Academic Article
|
Incidence of infection during efalizumab therapy for psoriasis: analysis of the clinical trial experience.
|
Academic Article
|
A randomized, open-label trial of continuous versus interrupted etanercept therapy in the treatment of psoriasis.
|
Academic Article
|
Clinical response in psoriasis patients discontinued from and then reinitiated on etanercept therapy.
|
Academic Article
|
Duration of remission of biologic agents for chronic plaque psoriasis.
|
Academic Article
|
Clinical efficacy of efalizumab in patients with chronic plaque psoriasis: results from three randomized placebo-controlled Phase III trials: part I.
|
Academic Article
|
From the Medical Board of the National Psoriasis Foundation: monitoring and vaccinations in patients treated with biologics for psoriasis.
|
Academic Article
|
Targeting TNFalpha rapidly reduces density of dendritic cells and macrophages in psoriatic plaques with restoration of epidermal keratinocyte differentiation.
|
Academic Article
|
Treatment of psoriasis with alefacept: correlation of clinical improvement with reductions of memory T-cell counts.
|
Academic Article
|
Safety and efficacy of ABT-874, a fully human interleukin 12/23 monoclonal antibody, in the treatment of moderate to severe chronic plaque psoriasis: results of a randomized, placebo-controlled, phase 2 trial.
|
Academic Article
|
The editor's roundtable: psoriasis, inflammation, and coronary artery disease.
|
Academic Article
|
From laboratory to clinic: rationale for biologic therapy.
|
Academic Article
|
Impact of adalimumab treatment on patient-reported outcomes: results from a Phase III clinical trial in patients with moderate to severe plaque psoriasis.
|
Academic Article
|
Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 5. Guidelines of care for the treatment of psoriasis with phototherapy and photochemotherapy.
|
Academic Article
|
Safety of efalizumab in adults with chronic moderate to severe plaque psoriasis: a phase IIIb, randomized, controlled trial.
|
Academic Article
|
Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 3. Guidelines of care for the management and treatment of psoriasis with topical therapies.
|
Academic Article
|
Ustekinumab significantly improves symptoms of anxiety, depression, and skin-related quality of life in patients with moderate-to-severe psoriasis: Results from a randomized, double-blind, placebo-controlled phase III trial.
|
Academic Article
|
A series of critically challenging case scenarios in moderate to severe psoriasis: a Delphi consensus approach.
|
Academic Article
|
Lessons learned from psoriatic plaques concerning mechanisms of tissue repair, remodeling, and inflammation.
|
Academic Article
|
The treatment of psoriasis and psoriatic arthritis: an interdisciplinary approach.
|
Academic Article
|
The new psoriasis pathway: toward a unified theory of immunopathogenesis.
|
Academic Article
|
Long-term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasis.
|
Academic Article
|
Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1).
|
Academic Article
|
A phase III, randomized, controlled trial of the fully human IL-12/23 mAb briakinumab in moderate-to-severe psoriasis.
|
Academic Article
|
Long-term efficacy and safety of adalimumab in patients with moderate to severe psoriasis treated continuously over 3 years: results from an open-label extension study for patients from REVEAL.
|
Academic Article
|
An update on the long-term safety experience of ustekinumab: results from the psoriasis clinical development program with up to four years of follow-up.
|
Academic Article
|
Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics.
|
Academic Article
|
Strategies for treatment with anti-tumor necrosis factor agents in psoriasis: maintaining efficacy and safety for the long haul.
|
Academic Article
|
AJC editor's consensus: psoriasis and coronary artery disease.
|
Academic Article
|
Guidelines of care for the management of psoriasis and psoriatic arthritis: section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents.
|
Academic Article
|
Anti-p40 antibodies ustekinumab and briakinumab: blockade of interleukin-12 and interleukin-23 in the treatment of psoriasis.
|
Academic Article
|
Ustekinumab: an evidence-based review of its effectiveness in the treatment of psoriasis.
|
Academic Article
|
Efficacy and safety of ABT-874, a monoclonal anti-interleukin 12/23 antibody, for the treatment of chronic plaque psoriasis: 36-week observation/retreatment and 60-week open-label extension phases of a randomized phase II trial.
|
Academic Article
|
Long-term safety experience of ustekinumab in patients with moderate to severe psoriasis (Part II of II): results from analyses of infections and malignancy from pooled phase II and III clinical trials.
|
Academic Article
|
Association between biologic therapies for chronic plaque psoriasis and cardiovascular events: a meta-analysis of randomized controlled trials.
|
Academic Article
|
Long-term efficacy of biologics in the treatment of psoriasis: what do we really know?
|
Academic Article
|
CD4+ T-cell-directed antibody responses are maintained in patients with psoriasis receiving alefacept: results of a randomized study.
|
Academic Article
|
Evolution of biologic therapies for the treatment of psoriasis.
|
Academic Article
|
Remittive effects of intramuscular alefacept in psoriasis.
|
Academic Article
|
The efficacy of alefacept in the treatment of chronic plaque psoriasis.
|
Academic Article
|
Extended efalizumab therapy improves chronic plaque psoriasis: results from a randomized phase III trial.
|
Academic Article
|
Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension study.
|
Academic Article
|
Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics.
|
Academic Article
|
Treating psoriasis with adalimumab.
|
Academic Article
|
Efficacy and safety of adalimumab across subgroups of patients with moderate to severe psoriasis.
|
Academic Article
|
Guidelines of care for the management of psoriasis and psoriatic arthritis: section 6. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: case-based presentations and evidence-based conclusions.
|
Academic Article
|
Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial through up to 3 years.
|
Academic Article
|
Rationale and early clinical data on IL-17 blockade in psoriasis.
|
Academic Article
|
Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's disease.
|
Academic Article
|
Unmet needs in the treatment of psoriasis.
|
Academic Article
|
A 52-week, open-label study of the efficacy and safety of ixekizumab, an anti-interleukin-17A monoclonal antibody, in patients with chronic plaque psoriasis.
|
Academic Article
|
Patient satisfaction and quality of life in psoriasis and psoriatic arthritis.
|
Academic Article
|
Updates on Psoriasis and Cutaneous Oncology: Proceedings from the 2013 MauiDerm Meeting.
|
Academic Article
|
A Delphi Consensus Approach to Challenging Case Scenarios in Moderate-to-Severe Psoriasis: Part 2.
|
Academic Article
|
Understanding therapeutic pathways and comorbidities in psoriasis.
|
Academic Article
|
A Delphi Consensus Approach to Challenging Case Scenarios in Moderate-to-Severe Psoriasis: Part 1.
|
Academic Article
|
New and emerging therapies in psoriasis.
|
Academic Article
|
Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1).
|
Academic Article
|
A Phase 2 Trial of Guselkumab versus Adalimumab for Plaque Psoriasis.
|
Academic Article
|
Effect of Ixekizumab Treatment on Work Productivity for Patients With Moderate-to-Severe Plaque Psoriasis: Analysis of Results From 3 Randomized Phase 3 Clinical Trials.
|
Academic Article
|
Clinical meaningfulness of complete skin clearance in psoriasis.
|
Academic Article
|
Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis.
|
Academic Article
|
Translating the Science of Psoriasis.
|
Academic Article
|
The tumour necrosis factor-alpha inhibitor adalimumab rapidly reverses the decrease in epidermal Langerhans cell density in psoriatic plaques.
|
Academic Article
|
A high level of clinical response is associated with improved patient-reported outcomes in psoriasis: analyses from a phase 2 study in patients treated with ixekizumab.
|
Academic Article
|
The experience of pain and redness in patients with moderate to severe plaque psoriasis.
|
Academic Article
|
Update on New and Emerging Therapies in the Management of Psoriasis.
|
Academic Article
|
Efficacy and safety observed during 24 weeks of efalizumab therapy in patients with moderate to severe plaque psoriasis.
|
Academic Article
|
Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis treated for up to 5 years in the PHOENIX 1 study.
|
Academic Article
|
Adalimumab retreatment successfully restores clinical response and health-related quality of life in patients with moderate to severe psoriasis who undergo therapy interruption.
|
Academic Article
|
Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis.
|
Academic Article
|
The inpatient burden of psoriasis in the United States.
|
Academic Article
|
Early development and qualitative evidence of content validity for the Psoriasis Symptom Inventory (PSI), a patient-reported outcome measure of psoriasis symptom severity.
|
Academic Article
|
Infliximab treatment results in significant improvement in the quality of life of patients with severe psoriasis: a double-blind placebo-controlled trial.
|
Academic Article
|
Early clinical response as a predictor of subsequent response to ixekizumab treatment: results from a phase II study of patients with moderate-to-severe plaque psoriasis.
|
Academic Article
|
Serious infections in hospitalized patients with psoriasis in the United States.
|
Academic Article
|
National Psoriasis Foundation clinical consensus on psoriasis comorbidities and recommendations for screening.
|
Academic Article
|
Clinical trial safety and mortality analyses in patients receiving etanercept across approved indications.
|
Academic Article
|
Validation of the Psoriasis Symptom Inventory (PSI), a patient-reported outcome measure to assess psoriasis symptom severity.
|
Academic Article
|
Safety results from a pooled analysis of randomized, controlled phase II and III clinical trials and interim data from an open-label extension trial of the interleukin-12/23 monoclonal antibody, briakinumab, in moderate to severe psoriasis.
|
Academic Article
|
The first World Psoriasis and Psoriatic Arthritis Conference.
|
Academic Article
|
Integrated safety analysis: short- and long-term safety profiles of etanercept in patients with psoriasis.
|
Academic Article
|
Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial.
|
Academic Article
|
Impact of brodalumab treatment on psoriasis symptoms and health-related quality of life: use of a novel patient-reported outcome measure, the Psoriasis Symptom Inventory.
|
Academic Article
|
Systemics to topicals in psoriasis: the unfilled need.
|
Academic Article
|
Efficacy of etanercept in an integrated multistudy database of patients with psoriasis.
|
Academic Article
|
Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial.
|
Academic Article
|
Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis.
|
Academic Article
|
Early clinical response to tofacitinib treatment as a predictor of subsequent efficacy: Results from two phase 3 studies of patients with moderate-to-severe plaque psoriasis.
|
Academic Article
|
Continuous dosing versus interrupted therapy with ixekizumab: an integrated analysis of two phase 3 trials in psoriasis.
|
Academic Article
|
Association of psoriasis and psoriatic arthritis with osteoporosis and pathological fractures.
|
Academic Article
|
Treating to Target-A Realistic Goal in Psoriasis?
|
Academic Article
|
The Evolving Landscape of Psoriasis Treatment.
|
Academic Article
|
Practical Strategies for Optimizing Management of Psoriasis.
|
Academic Article
|
Common and Not-So-Common Comorbidities of Psoriasis.
|
Academic Article
|
Core Outcome Sets for Psoriasis Clinical Trials: Definition, Consensus, and Acceptance.
|
Academic Article
|
Efficacy of Guselkumab Compared With Adalimumab and Placebo for Psoriasis in Specific Body Regions: A Secondary Analysis of 2 Randomized Clinical Trials.
|
Academic Article
|
Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials.
|
Academic Article
|
Long-term optimization of outcomes with flexible adalimumab dosing in patients with moderate to severe plaque psoriasis.
|
Academic Article
|
Measurement Properties of the Psoriasis Symptom Inventory Electronic Daily Diary in Patients with Moderate to Severe Plaque Psoriasis.
|
Academic Article
|
Poor early response to methotrexate portends inadequate long-term outcomes in patients with moderate-to-severe psoriasis: Evidence from 2 phase 3 clinical trials.
|
Academic Article
|
Efficacy of guselkumab in subpopulations of patients with moderate-to-severe plaque psoriasis: a pooled analysis of the phase III VOYAGE 1 and VOYAGE 2 studies.
|
Academic Article
|
Impact of previous biologic use on the efficacy and safety of brodalumab and ustekinumab in patients with moderate-to-severe plaque psoriasis: integrated analysis of the randomized controlled trials AMAGINE-2 and AMAGINE-3.
|
Academic Article
|
Phase 2 Trial of Selective Tyrosine Kinase 2 Inhibition in Psoriasis.
|
Academic Article
|
IL-23 inhibitors for moderate-to-severe psoriasis.
|
Academic Article
|
Efficacy and safety of ixekizumab over 4 years of open-label treatment in a phase 2 study in chronic plaque psoriasis.
|
Academic Article
|
Correlation of psoriasis activity with socioeconomic status: cross-sectional analysis of patients enrolled in the Psoriasis Longitudinal Assessment and Registry (PSOLAR).
|
Academic Article
|
Anxiety and depression in patients with moderate-to-severe psoriasis and comparison of change from baseline after treatment with guselkumab vs. adalimumab: results from the Phase 3 VOYAGE 2 study.
|
Academic Article
|
Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities.
|
Academic Article
|
Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics.
|
Academic Article
|
Guselkumab Efficacy after Withdrawal Is Associated with Suppression of Serum IL-23-Regulated IL-17 and IL-22 in Psoriasis: VOYAGE 2 Study.
|
Academic Article
|
Sustained and continuously improved efficacy of tildrakizumab in patients with moderate-to-severe plaque psoriasis.
|
Academic Article
|
Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis with phototherapy.
|
Academic Article
|
Ixekizumab sustains high level of efficacy and favourable safety profile over 4 years in patients with moderate psoriasis: results from UNCOVER-3 study.
|
Academic Article
|
Risankizumab in moderate-to-severe plaque psoriasis.
|
Academic Article
|
Consistent responses with guselkumab treatment in Asian and non-Asian patients with psoriasis: An analysis from VOYAGE 1 and VOYAGE 2.
|
Academic Article
|
Ixekizumab treatment and the impact on SF-36: results from three pivotal phase III randomised controlled trials in patients with moderate-to-severe plaque psoriasis.
|
Academic Article
|
Defining drug-free remission of skin disease in patients with plaque psoriasis.
|
Academic Article
|
Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis in pediatric patients.
|
Academic Article
|
Maintenance of clinical response and consistent safety profile with up to 3 years of continuous treatment with guselkumab: Results from the VOYAGE 1 and VOYAGE 2 trials.
|
Academic Article
|
A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 12-week efficacy, safety and speed of response from a randomized, double-blinded trial.
|
Academic Article
|
Characterization of Patients with Psoriasis in Challenging-to-Treat Body Areas in the Corrona Psoriasis Registry.
|
Academic Article
|
Comparative Effectiveness Studies for Psoriasis-The Methods Matter.
|
Academic Article
|
Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management of psoriasis with systemic nonbiologic therapies.
|
Academic Article
|
Efficacy of risankizumab in patients with moderate-to-severe plaque psoriasis by baseline demographics, disease characteristics and prior biologic therapy: an integrated analysis of the phase III UltIMMa-1 and UltIMMa-2 studies.
|
Academic Article
|
Disease activity and treatment efficacy using patient-level Psoriasis Area and Severity Index scores from tildrakizumab phase 3 clinical trials.
|
Academic Article
|
Long-term efficacy of certolizumab pegol for the treatment of plaque psoriasis: 3-year results from two randomized phase III trials (CIMPASI-1 and CIMPASI-2).
|
Academic Article
|
Joint AAD-NPF Guidelines of care for the management and treatment of psoriasis with topical therapy and alternative medicine modalities for psoriasis severity measures.
|
Academic Article
|
Maintenance of Response Through up to 4 Years of Continuous Guselkumab Treatment of Psoriasis in the VOYAGE 2 Phase 3 Study.
|
Academic Article
|
Effect of Risankizumab on Patient-Reported Outcomes in Moderate to Severe Psoriasis: The UltIMMa-1 and UltIMMa-2 Randomized Clinical Trials.
|
Academic Article
|
Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial.
|
Academic Article
|
Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial.
|
Academic Article
|
Efficacy, safety, usability, and acceptability of risankizumab 150?mg formulation administered by prefilled syringe or by an autoinjector for moderate to severe plaque psoriasis.
|
Academic Article
|
Five-year maintenance of clinical response and health-related quality of life improvements in patients with moderate-to-severe psoriasis treated with guselkumab: results from VOYAGE 1 and VOYAGE 2.
|
Academic Article
|
Long-term safety of risankizumab from 17 clinical trials in patients with moderate-to-severe plaque psoriasis.
|
Academic Article
|
Molecular and clinical effects of selective tyrosine kinase 2 inhibition with deucravacitinib in psoriasis.
|
Academic Article
|
Deucravacitinib in Moderate to Severe Psoriasis: Clinical and Quality-of-Life Outcomes in a Phase 2 Trial.
|
Academic Article
|
Efficacy of Risankizumab versus Secukinumab in Patients with Moderate-to-Severe Psoriasis: Subgroup Analysis from the IMMerge Study.
|
Academic Article
|
Bimekizumab Safety in Patients With Moderate to Severe Plaque Psoriasis: Pooled Results From Phase 2 and Phase 3 Randomized Clinical Trials.
|
Academic Article
|
Anti-IL 23 biologics for the treatment of plaque psoriasis.
|
Academic Article
|
Deucravacitinib in moderate-to-severe psoriasis.
|
Academic Article
|
Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 Program fOr Evaluation of TYK2 inhibitor psoriasis second trial.
|
Academic Article
|
Treatment of plaque psoriasis with deucravacitinib (POETYK PSO-2 study): a plain language summary.
|
Academic Article
|
Methotrexate for inflammatory skin disease in pediatric patients: Consensus treatment guidelines.
|
Academic Article
|
Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial.
|
Academic Article
|
Rethinking eligibility creep.
|
Academic Article
|
Efficacy and safety of subcutaneous spesolimab for the prevention of generalised pustular psoriasis flares (Effisayil 2): an international, multicentre, randomised, placebo-controlled trial.
|
Academic Article
|
The Epidemiology of Palmoplantar Pustulosis: An Analysis of Multiple Health Insurance Claims and Electronic Health Records Databases.
|
Academic Article
|
Bimekizumab safety in patients with moderate-to-severe plaque psoriasis: pooled data from up to 3 years of treatment in randomized phase III trials.
|
Academic Article
|
Meaningful Change Thresholds for the Psoriasis Symptoms and Signs Diary: A Secondary Analysis of a Randomized Clinical Trial.
|
Academic Article
|
Association between biological immunotherapy for psoriasis and time to incident inflammatory arthritis: a retrospective cohort study.
|
Academic Article
|
Differentiating biologics to prevent psoriatic arthritis in patients with psoriasis - Authors' reply.
|
Academic Article
|
The Efficacy and Safety of Bimekizumab for Plaque Psoriasis: An Expert Consensus Panel.
|
Academic Article
|
Deucravacitinib in moderate-to-severe plaque psoriasis: Pooled safety and tolerability over 52?weeks from two phase 3 trials (POETYK PSO-1 and PSO-2).
|
Academic Article
|
Bimekizumab for the treatment of psoriasis.
|